Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783625 · ClinicalTrials.gov registry record · Phase 1
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
A Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 11
- Study locations
NCT02783625: Active Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02783625 is a Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 114 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (76% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02783625, a Phase 1 study of Lymphoma and Relapsed/Refractory T-cell Lymphomas, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety of a study drug called duvelisib.
Primary Outcome
There will be two parallel phase I studies using the 3+3 dose escalation scheme
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG Romidepsin
- DRUG duvelisib
Study Locations (11)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Limitied protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Missouri
- University of Washington School of Medicine in St. Louis - St Louis
- Washington University School of Medicine - St Louis
California
- Stanford University Medical Center - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT02783625 still lists
NCT02783625 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Bortezomib is the first listed.
NCT02783625 lists 11 locations in 5 states (New York, New Jersey, Missouri).
Frequently Asked Questions
What is clinical trial NCT02783625 about?
NCT02783625 is a clinical study titled "Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas". The purpose of this study is to test the safety of a study drug called duvelisib.
What is the current status of trial NCT02783625?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2016-05. Estimated completion is 2026-05.
What conditions does trial NCT02783625 study?
This clinical trial studies the following conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas.
What interventions are being tested in trial NCT02783625?
The interventions under investigation include: Bortezomib (DRUG), Romidepsin (DRUG), duvelisib (DRUG).
Who is sponsoring clinical trial NCT02783625?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02783625 being conducted?
This trial has 11 study locations across California, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02783625's enrollment target sits among peer trials
114 71st of 299 higher than 229 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia